Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market

Description:  
Cancer is a group of diseases characterized by abnormal cell growth. It is a multi-step process, as a single mutation is almost certainly insufficient to cause a cell to become malignant. A number of cellular processes must be deregulated to allow cells to proliferate uncontrollably while evading apoptosis. Initially, key cell growth, proliferative and pro-apoptotic signaling pathways are deregulated in most cancers. These signaling pathways enable cell survival, continued proliferation, and the avoidance of programmed cell death.

It is now widely believed that many tumors express antigens that can be identified by the adaptive immune system, and that can therefore potentially be used to produce an anti-tumor immune response. The immune system is believed to have the greatest potential in terms of treating cancer, as there is evidence tumors are recognized by the immune system, and this tumor-specific immune response is due to the recognition of tumor antigens. However, in many cancers, disease progression is also accompanied by immune suppression, which hinders an effective anti-tumor response and tumor elimination.

Over the past few decades cancer immunotherapies have developed into important therapeutic options for some types of cancer. Some of these therapies generally enhance the activity of the body's immune system, while others drive the immune system to target specific cancer cells.

The different types of cancer immunotherapies used to treat cancer include monoclonal antibodies (mAbs) directed at specific tumor-associated antigens (TAA); immune checkpoint inhibitors, which target key proteins involved in the immune response, such as programmed cell death-1 (PD-1); cancer vaccines, which can be used to stimulate an immune response in a patient; and non-specific immunotherapies, which are therapies that do not target cancer cells specifically, but stimulate the immune system in a more general way, such as interferon therapy.

Overall, there are 2,037 products in active development in the cancer immunotherapy pipeline. This makes it a notable portion of the entire oncology pipeline, and reflects the strong interest in this class of therapy in product development. This is due to growing clinical rationale behind developing such therapies, and the willingness of drug developers to invest in novel therapeutics, which will offer significant product differentiation from market competitors.

The leading indications in terms of cancer immunotherapy product development are breast cancer, melanoma, non-small-cell lung cancer (NSCLC) and ovarian cancer, which are the focus of this report. This is based on the high level of activity in terms of cancer immunotherapy product development in these specific oncology indications, with the aforementioned indications ranking highest in this regard.

The cancer immunotherapies market already consists of some commercially successful products.

- Which classes of drug dominate the market?
- What additional benefits have newly approved therapies brought to the market?

The cancer immunotherapies pipeline is vast, with a significant degree of diversity in terms of molecule types and targets.

- Which molecular targets appear most frequently in the pipeline?
- What are the commercial prospects for the most promising late-stage pipeline products?

The cancer immunotherapies market is forecast to rise from a value of $16.9 billion in 2015 to $75.8 billion in 2022, at a compound annual growth rate of 23.9%.

- Which products are forecast to drive this substantial degree of growth?
- Will generic competition have a significant impact on the market over the forecast period?

The company landscape is growing increasingly competitive.

- What are the leading companies in terms of market share?
- Which companies are forecast to experience the greatest growth in market share?
- What are the drivers of growth for key companies in the market?
- How dependent are the key companies on this disease cluster for revenue?
- Which companies rely heavily on this disease cluster for revenue?

Reasons to buy

This report will allow you to:

- Understand the current clinical and commercial landscape through a comprehensive study of disease epidemiology, pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report, which includes breast cancer, melanoma, NSCLC and ovarian cancer.
- Assess the current treatment landscape, with product profiles covering prominent marketed therapies, including revenue forecasts.
- Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
- Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from cancer immunotherapy products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
- Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals.

Contents:

1.1 List of Tables
1.2 List of Figures

2 Introduction
  2.1 Therapy Area Introduction
  2.2 Epidemiology
    2.2.1 Breast Cancer
    2.2.2 Melanoma
    2.2.3 Non-Small-Cell Lung Cancer
    2.2.4 Ovarian Cancer
  2.3 Pathophysiology and Etiology
    2.3.1 Breast Cancer
    2.3.2 Melanoma
    2.3.3 Non-Small-Cell Lung Cancer
    2.3.4 Ovarian Cancer
  2.4 Symptoms
    2.4.1 Breast Cancer
    2.4.2 Melanoma
    2.4.3 NSCLC
    2.4.4 Ovarian Cancer
  2.5 Diagnosis and Disease Staging
    2.5.1 Breast Cancer
    2.5.2 Melanoma
    2.5.3 Non-Small-Cell Lung Cancer
    2.5.4 Ovarian Cancer
  2.6 Prognosis
    2.6.1 Breast Cancer
    2.6.2 Melanoma
    2.6.3 Non-Small-Cell Lung Cancer
    2.6.4 Ovarian Cancer
2.7 Treatment

3 Key Marketed Products
3.1 Overview
3.2 Rituxan/MabThera - Roche
3.3 Revlimid (lenalidomide) - Celgene
3.4 Yervoy (ipilimumab) - Bristol-Myers Squibb
3.5 Opdivo (nivolumab) - Bristol-Myers Squibb
3.6 Keytruda (pembrolizumab) - Merck & Co.
3.7 Pomalyst (pomalidomide) - Celgene
3.8 Gardasil/Gardasil 9 (human papillomavirus [types 6, 11, 16, 18] (quadrivalent) vaccine-prophylactic vaccine) - Merck & Co.
3.9 Provenge (sipuleucel-T) - Valeant Pharmaceuticals
3.10 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Conclusion
4.5 Assessment of Key Pipeline Products
4.5.1 Durvalumab - AstraZeneca
4.5.2 Durvalumab + Tremelimumab - AstraZeneca
4.5.3 Tisagenlecleucel-T (CTL-019) - Novartis
4.5.4 KTE-C19 - Kite Pharma
4.5.5 Avelumab - Merck KGaA/Pfizer
4.5.6 Epacadostat - Incyte Corporation
4.5.7 Conclusion

5 Multi-scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Immune-Checkpoint Proteins
5.3.2 Tumor Associated Antigens
5.3.3 Cancer Vaccines
5.3.4 Signal Transduction
5.4 Revenue and Market Share Analysis by Company
5.4.1 Celgene - Revlimid to Maintain Celgene's Position as Market Leader
5.4.2 Bristol-Myers Squibb - Opdivo to Drive Revenue from Cancer Immunotherapies
5.4.3 Roche - Revenue Generated from Cancer Immunotherapies Forecast to Grow due to Tecentriq and Gazyva
5.4.4 Merck & Co. - Keytruda Key to Cancer Immunotherapy Market Growth
5.4.5 AstraZeneca - New Approvals to Mark Entry of AstraZeneca in Cancer Immunotherapy Market
5.4.6 Novartis - Cancer Immunotherapies Constitute Small Proportion of Vast Overall Revenue
5.4.7 Amgen - Innovative Imlygic to Help Generate above $1 Billion from Cancer Immunotherapy Market
5.4.8 Pfizer - Overall Cancer Immunotherapy Revenue to Surpass $1 Billion by 2022 due to PD-L1-Inhibitor Avelumab
5.4.9 Kite Pharma - KTE-C19 CAR to Drive Revenue Growth in Forecast Period

6 Company Analysis and Positioning
6.1 Company Landscape
6.2 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deal by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Molecular Target and Value
7.1.4 Table for Licensing Deals Valued above $500m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals Valued above $100m

8 Appendix
8.1 Bibliography
8.2 All Pipeline Drugs by Phase of Development
8.2.1 Discovery
8.2.2 Preclinical
8.2.3 IND/CTA-filed
8.2.4 Phase I
8.2.5 Phase II
8.2.6 Phase III
8.2.7 Pre-registration
8.2.8 Unknown
8.3 Abbreviations
8.4 Disease List
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape

List of Tables:

Table 1: Cancer Immunotherapies Market, Global, Epidemiology of Key Oncology Indications, 2016
Table 2: Cancer Immunotherapies Market, Global, Regional Lymph Node and Metastasis Staging, 2016
Table 3: Cancer Immunotherapies Market, Global, Eastern Co-operative Oncology Group Criteria, 2016
Table 4: Cancer Immunotherapies Market, Global, Breast Cancer Histopathological and Molecular Classification, 2016
Table 5: Cancer Immunotherapies Market, Global, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2016
Table 6: Cancer Immunotherapies Market, Global, Ovarian Cancer Stage and Survival Rates (%), 2016
Table 7: Cancer Immunotherapies Market, US, Lung Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2016
Table 8: Cancer Immunotherapies Market, US, Ovarian Cancer Stage at Diagnosis and Five-year Relative Survival (%), 2016
Table 9: Cancer Immunotherapies Market, Global, Approved Indications for Rituxan, 2016
Table 10: Cancer Immunotherapies Market, Global, Approved Indications for Revlimid, 2016
Table 11: Cancer Immunotherapies Market, Global, Approved Indications for Yervoy, 2016
Table 12: Cancer Immunotherapies Market, Global, Approved Indications for Opdivo, 2016
Table 13: Cancer Immunotherapies Market, Global, Approved Indications for Keytruda, 2016
Table 14: Cancer Immunotherapies Market, Global, Approved Indications for Pomalyst, 2016
Table 15: Cancer Immunotherapies Market, Global, Approved Indications for Gardasil, 2016
Table 16: Cancer Immunotherapies Market, Global, Approved Indications for Provenge, 2016
Table 17: Cancer Immunotherapies Market, Global, Forecast Revenue by Company, 2016
Table 18: Cancer Immunotherapies Market, Global, Licensing Deals Valued above $500m, 2006-2016
Table 19: Cancer Immunotherapies Market, Global, Co-development Deals Valued above $100m, 2006-2016
Table 20: Cancer Immunotherapies Market, Global, Pipeline Products, Discovery, 2016
Table 21: Cancer Immunotherapies Market, Global, Pipeline Products, Preclinical, 2016
Table 22: Cancer Immunotherapies Market, Global, Pipeline Products, IND/CTA filed, 2016
Table 23: Cancer Immunotherapies Market, Global, Pipeline Products, Phase I, 2016
Table 24: Cancer Immunotherapies Market, Global, Pipeline Products, Phase II, 2016
Table 25: Cancer Immunotherapies Market, Global, Pipeline Products, Phase III, 2016
Table 26: Cancer Immunotherapies Market, Global, Pipeline Products, Pre-Registration, 2016
Table 27: Cancer Immunotherapies Market, Global, Pipeline Products, Unknown, 2016
List of Figures:

Figure 1: Cancer Immunotherapies Market, Global, Epidemiology Patterns for Breast Cancer, 2015-2023
Figure 2: Cancer Immunotherapies Market, Global, Epidemiology Patterns for Melanoma, 2015-2023
Figure 3: Cancer Immunotherapies Market, Global, Epidemiology Patterns for NSCLC, 2015-2023
Figure 4: Cancer Immunotherapies Market, Global, Epidemiology Patterns for Ovarian Cancer, 2015-2023
Figure 5: Cancer Immunotherapies Market, Global, NSCLC Molecular Characteristic Frequency (%)
Figure 6: Cancer Immunotherapies Market, Global, Key Marketed Products and Approved Indications, 2016
Figure 7: Cancer Immunotherapies Market, Global, Annual Revenue for Rituxan ($bn), 2006-2022
Figure 8: Cancer Immunotherapies Market, Global, Annual Revenue for Revlimid ($bn), 2006-2022
Figure 9: Cancer Immunotherapies Market, Global, Annual Revenue for Yervoy ($bn), 2011-2022
Figure 10: Cancer Immunotherapies Market, Global, Annual Revenue for Opdivo ($bn), 2014-2022
Figure 11: Cancer Immunotherapies Market, Global, Annual Revenue for Keytruda ($bn), 2014-2022
Figure 12: Cancer Immunotherapies Market, Global, Annual Revenue for Pomalyst ($bn), 2013-2022
Figure 13: Cancer Immunotherapies Market, Global, Annual Revenue for Gardasil ($bn), 2006-2022
Figure 14: Cancer Immunotherapies Market, Global, Annual Revenue for Provenge ($m), 2010-2022
Figure 15: Cancer Immunotherapies Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
Figure 16: Cancer Immunotherapies Market, Global, Pipeline for Cancer Immunotherapies by Stage of Development, Molecule Type and Program Type, 2016
Figure 17: Cancer Immunotherapies Market, Global, Pipeline for Key Cancers by Stage of Development, 2016
Figure 18: Cancer Immunotherapies Market, Global, Pipeline for Key Cancers by Molecule Type, 2016
Figure 19: Cancer Immunotherapies Market, Global, Pipeline for Cancer Immunotherapies by Molecular Target, 2016
Figure 20: Cancer Immunotherapies Market, Global, Pipeline for Key Cancers by Molecular Target, 2016
Figure 21: Cancer Immunotherapies Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
Figure 22: Cancer Immunotherapies Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
Figure 23: Cancer Immunotherapies Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 24: Cancer Immunotherapies Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 25: Cancer Immunotherapies Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
Figure 26: Cancer Immunotherapies Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
Figure 27: Cancer Immunotherapies Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
Figure 28: Cancer Immunotherapies Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
Figure 29: Cancer Immunotherapies Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016
Figure 30: Cancer Immunotherapies Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
Figure 31: Cancer Immunotherapies Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 32: Cancer Immunotherapies Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 33: Cancer Immunotherapies Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2016
Figure 34: Cancer Immunotherapies Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
Figure 35: Cancer Immunotherapies Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 36: Cancer Immunotherapies Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 37: Cancer Immunotherapies Market, Global, Revenue for Durvalumab ($bn), 2017-2022
Figure 38: Cancer Immunotherapies Market, Global, Revenue for Durvalumab and Tremelimumab ($bn), 2018-2022
Figure 39: Cancer Immunotherapies Market, Global, Revenue for Tisagenlecleucel-T ($bn), 2017-2022
Figure 40: Cancer Immunotherapies Market, Global, Revenue for KTE-C19 ($m), 2017-2022
Figure 41: Cancer Immunotherapies Market, Global, Revenue for Avelumab ($m), 2017-2022
Figure 42: Cancer Immunotherapies Market, Global, Revenue for Epacadostat ($m), 2018-2022
Figure 43: Cancer Immunotherapies Market, Global, Market Size ($bn), 2015-2022
Figure 44: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022
Figure 45: Cancer Immunotherapies Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015-2022
Figure 46: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Immune-Checkpoint Proteins ($bn), 2015-2022
Figure 47: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Tumor Associated Antigens ($bn), 2015-2022
Figure 48: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Cancer Vaccines ($bn), 2015-2022
Figure 49: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Signal Transduction ($bn), 2015-2022
Figure 50: Cancer Immunotherapies Market, Global, Company Analysis Matrix, 2015-2022
Figure 51: Cancer Immunotherapies Market, Global, Forecast Market Share by Company (%), 2015-2022
Figure 52: Cancer Immunotherapies Market, Global, Companies by Compound Annual Growth Rate (%), Base Year-2022
Figure 53: Cancer Immunotherapies Market, Global, Revenue by Product Type, 2015-2022
Figure 54: Cancer Immunotherapies Market, Global, Celgene Annual Revenue Forecast ($bn), 2015-2022
Figure 55: Cancer Immunotherapies Market, Global, Bristol-Myers Squibb Annual Revenue ($bn), 2015-2022
Figure 56: Cancer Immunotherapies Market, Global, Roche Annual Revenue ($bn), 2015-2022
Figure 57: Cancer Immunotherapies Market, Global, Merck & Co. Annual Revenue ($bn), 2015-2022
Figure 58: Cancer Immunotherapies Market, Global, AstraZeneca Annual Revenue ($bn), 2017-2022
Figure 59: Cancer Immunotherapies Market, Global, Novartis Annual Revenue ($bn), 2015-2022
Figure 60: Cancer Immunotherapies Market, Global, Amgen Annual Revenue ($bn), 2015-2022
Figure 61: Cancer Immunotherapies Market, Global, Pfizer Annual Revenue ($bn), 2016-2022
Figure 62: Cancer Immunotherapies Market, Global, Kite Pharma Annual Revenue ($m), 2017-2022
Figure 63: Cancer Immunotherapies Market, Global, Cluster by Growth and Market Share, 2015-2022
Figure 64: Cancer Immunotherapies Market, Global, Companies by Type, 2016
Figure 65: Cancer Immunotherapies Market, Global, High-Activity and Late-Stage Developers by Level of Specialization, 2016
Figure 66: Cancer Immunotherapies Market, Global, Proportion of Total Company Revenue Attributed to Cancer Immunotherapies, 2015-2022
Figure 67: Cancer Immunotherapies Market, Global, Licensing Deals by Region, Year and Value, 2006-2016
Figure 68: Cancer Immunotherapies Market, Global, Licensing Deals by Indication and Value, 2006-2016
Figure 69: Cancer Immunotherapies Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016
Figure 70: Cancer Immunotherapies Market, Global, Licensing Deals by Molecule Type and Target, 2006-2016
Figure 71: Cancer Immunotherapies Market, Global, Co-development Deals by Region, Year and Value, 2006-2016
Figure 72: Cancer Immunotherapies Market, Global, Co-development Deals by Indication, 2006-2016
Figure 73: Cancer Immunotherapies Market, Global, Co-development Deals by Stage of Development and Value, 2006-2016
Figure 74: Cancer Immunotherapies Market, Global, Co-development Deals by Molecule Type and Target, 2006-2016

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/4027220/](http://www.researchandmarkets.com/reports/4027220/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Cancer Immunotherapies Market to 2022 - Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market
Web Address: http://www.researchandmarkets.com/reports/4027220/
Office Code: SC2GBN2S

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Formats</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>☐</td>
<td>USD 4995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>☐</td>
<td>USD 9990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>☐</td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

- Pay by check: Please post the check, accompanied by this form, to:
  Research and Markets,
  Guinness Center,
  Taylors Lane,
  Dublin 8,
  Ireland.

- Pay by wire transfer: Please transfer funds to:
  Account number 833 130 83
  Sort code 98-53-30
  Swift code ULSBIE2D
  IBAN number IE78ULSB98533083313083
  Bank Address Ulster Bank,
  27-35 Main Street,
  Blackrock,
  Co. Dublin,
  Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ........................................................

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World